ArticleBMC neurology2025
Value of blood biomarkers in the diagnosis of Parkinson's disease: a case-control study from Xinjiang.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBased on the data of Parkinson's disease patients in Xinjiang, China, to explore the clinical application value of blood biomarkers in diagnosing Parkinson's disease patients.
methodsThe research subjects were patients with Parkinson's disease who were diagnosed and hospitalized at the Second Affiliated Hospital of Xinjiang Medical University between January 2021 and January 2023 and those who underwent health check-ups at the hospital, 243 and 249 cases were included, respectively, and those who underwent health check-ups were used as a healthy control group of the Parkinson's disease patient group.
resultsSignificant differences in age, systolic blood pressure, cystatin C, and uric acid distributions were found between healthy controls and Parkinson's patients (P < 0.05), and multivariate analysis showed that there was a correlation between body mass index, uric acid, and Parkinson's disease (P < 0.05), and that those who were overweight or obese, and those who had a low level of uric acid, had a greater probability of suffering from Parkinson's disease (B > 0). There were significant differences in gender, cystatin C, and urea between Parkinson's patients with a disease duration of < 5 years and those with a disease duration of ≥ 5 years (P < 0.05). In multivariate analysis, there was a correlation between gender and duration of Parkinson's disease (P < 0.05), and the duration of the disease was greater in male patients than in females.
conclusionUric acid combined with body mass index is informative for early screening of Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.